Krystal Biotech
KRYS
108 hedge funds and large institutions have $836M invested in Krystal Biotech in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
34% more capital invested
Capital invested by funds: $623M → $836M (+$213M)
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
10% more funds holding
Funds holding: 98 → 108 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.88% less ownership
Funds ownership: 73.48% → 70.6% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.5M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$9.01M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$8.64M |
| 4 |
JP Morgan Chase
New York
|
+$7.67M |
| 5 |
DP
DSAM Partners
London,
United Kingdom
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$22.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.18M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.17M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.84M |
KRYS Hedge Fund Activity: Q4 2020 in Review
108 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2020, worth a combined $836M — up 34% from $623M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KRYS positions and 10 closed out — a net gain of 10 holders — while 35 added to existing stakes and 31 trimmed.
The largest buyer was BlackRock, adding an estimated $10.5M. The largest seller was Victory Capital Management, exiting entirely with an estimated $22.6M sold.
- 108 institutional investors held Krystal Biotech (KRYS) as of Q4 2020, up from 98 in Q3 2020.
- Funds reported $836M of Krystal Biotech stock for Q4 2020, up 34% quarter-over-quarter.
- 20 funds opened new Krystal Biotech positions in Q4 2020 and 10 closed out, a net change of +10 holders.
- The largest Krystal Biotech buyer in Q4 2020 was BlackRock, an estimated $10.5M added.
- The largest Krystal Biotech seller in Q4 2020 was Victory Capital Management, an estimated $22.6M sold.
Based on aggregated 13F filings for Q4 2020.